ORKA ORUKA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ORUKA THERAPEUTICS INC reported revenue of n/a, net income of −$41.2M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
ORKA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$122M, net income −$105M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$88.1M, net income −$83.7M (margin n/a), EPS −$3.87
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$7.30M, net income −$5.34M (margin n/a), EPS −$0.37
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$10.6M, net income −$9.93M (margin n/a), EPS −$0.69
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$19.3M, net income −$19.3M (margin n/a), EPS −$1.39
ORKA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$41.2M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income −$31.8M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$29.6M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$30.3M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$24.6M, EPS −$0.46
- Quarter ended Mar 31, 2025: revenue n/a, net income −$21.0M, EPS −$0.40
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$30.8M, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$28.6M, EPS −$1.46
- Quarter ended Jun 30, 2024: revenue n/a, net income −$22.2M, EPS −$6.96
- Quarter ended Mar 31, 2024: revenue $0, net income −$2.01M, EPS −$0.14
- Quarter ended Dec 31, 2023: revenue n/a, net income −$1.09M, EPS −$0.08
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.42M, EPS −$0.10
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.48M, EPS −$0.10
- Quarter ended Mar 31, 2023: revenue $0, net income −$1.35M, EPS −$0.09
- Quarter ended Dec 31, 2022: revenue n/a, net income −$1.17M, EPS −$0.08
- Quarter ended Sep 30, 2022: revenue n/a, net income −$2.33M, EPS −$0.16
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.15M, EPS −$0.22
- Quarter ended Mar 31, 2022: revenue $0, net income −$3.27M, EPS −$0.23
- Quarter ended Dec 31, 2021: revenue n/a, net income −$5.68M, EPS −$0.39
- Quarter ended Sep 30, 2021: revenue n/a, net income −$4.71M, EPS −$0.33
ORKA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$88.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$57.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$5.01M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$10.9M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$18.8M, share buybacks n/a
ORKA balance sheet
- Jun 30, 2026: cash $268M, total assets $1.14B, total liabilities $24.8M, shareholders' equity $1.11B
- Mar 31, 2026: cash $49.5M, total assets $504M, total liabilities $17.8M, shareholders' equity $487M
- Dec 31, 2025: cash $46.9M, total assets $489M, total liabilities $16.7M, shareholders' equity $472M
- Sep 30, 2025: cash $91.3M, total assets $509M, total liabilities $22.5M, shareholders' equity $487M
- Jun 30, 2025: cash $65.4M, total assets $357M, total liabilities $13.8M, shareholders' equity $344M
- Mar 31, 2025: cash $83.6M, total assets $377M, total liabilities $12.4M, shareholders' equity $365M
- Dec 31, 2024: cash $61.6M, total assets $396M, total liabilities $13.8M, shareholders' equity $382M
- Sep 30, 2024: cash $411M, total assets $414M, total liabilities $18.9M, shareholders' equity $342M
Is ORKA profitable?
No. ORUKA THERAPEUTICS INC lost $133M over the last four quarters.